Plasma homocysteine and folate levels in patients with chronic plaque psoriasis

British Journal of Dermatology

Volumn 155, Issue 6, 2006, Pages 1165-1169

  Malerba, M ^a   Gisondi, P ^b   Radaeli, A ^a   Sala, R ^a   Calzavara Pinton, P G ^a   Girolomoni, G ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Cardiovascular risk; Folic acid; Homocysteine; Psoriasis

Indexed keywords

ALCOHOL; CAFFEINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ADULT; AGED; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CHRONIC DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PSORIASIS;

EID: 33750925900     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07503.x     Document Type: Article

References (39)

1. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 2006; 8:100-6.
2. Kazemi MB, Eshraghian K, Omrani GR et al. Homocysteine level and coronary artery disease. Angiology 2006; 57:9-14.
3. Ozkan Y, Ozkan E, Simsek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002; 82:269-77.
4. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for disease: an overview. Clin Chem Lab Med 2001; 39:666-74.
5. Nygård O, Nordrehaud JE, Refsum H. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-6.
6. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49:31-62.
7. Bots ML, Launer LJ, Lindemans J. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999; 159:38-44.
8. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277:1775-81.
9. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998; 29:2478-83.
10. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis - mechanism for injury. Eur Heart J 2000; 21:967-74.
11. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-50.
12. Panagiotakos DB, Pitsavos C, Zeimbekis A et al. The association between lifestyle-related factors and plasma homocysteine levels in healthy individuals from the 'ATTICA' study. Int J Cardiol 2005; 98:471-7.
13. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996; 19:171-8.
14. Markus HS, Ali N, Swaminathan R. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28:1739-43.
15. Hu R, Zhang XX, Wang WQ et al. Smoking, homocysteine and degree of arteriolar retinopathy. Atherosclerosis 2005; 183:95-100.
16. Masse PG, Dosy J, Cole DE et al. Elevation of plasma homocysteine in natural menopause can not be explained by a lack of vitamin coenzyme availability: relevance to the risk of cardiovascular disease. J Nutr Health Aging 2005; 9:59-64.
17. Carlsen SM, Jacobsen G, Vatten L, Romundstad P. In pregnant women who smoke, caffeine consumption is associated with an increased level of homocysteine. Acta Obstet Gynecol Scand 2005; 84:1049-54.
18. Selhub J, Jacques PF, Wilson PW et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-8.
19. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67:263-70.
20. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19:225-30.
21. Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141:1527-34.
22. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61-7.
23. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
24. Hild DH. Folate losses from the skin in exfoliative dermatitis. Arch Intern Med 1969; 123:51-7.
25. Fry L, Macdonald A, Almeyda J et al. The mechanism of folate deficiency in psoriasis. Br J Dermatol 1971; 84:539-44.
26. Touraine R, Revuz J, Zittoun J et al. Study of folate in psoriasis: blood levels, intestinal absorption and cutaneous loss. Br J Dermatol 1973; 89:335-4.
27. Scarpa R, Manguso F, D'Arienzo A. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000; 27:1241-6.
28. Schatteman L, Mielants H, Veys EM. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995; 22:680-3.
29. Kural BV, Örem A, Çimşit B et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332:23-30.
30. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-57.
31. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:1593-600.
32. Kanani PM, Sinkey CA, Browning RL. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100:1161-8.
33. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 1998; 351:263.
34. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
35. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-75.
36. Bonaa KH, Njolstad I, Ueland PM et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-88.
37. Lonn E, Yusuf S, Arnold MJ et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567-77.
38. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005; 53:652-9.
39. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154:1169-74.